기저치를 가진 생물학적 동등성 평가의 통계적 고찰: 내인성 제제사례연구
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박상규 | - |
dc.contributor.author | 김상영 | - |
dc.date.available | 2019-03-08T05:58:09Z | - |
dc.date.issued | 2018-05 | - |
dc.identifier.issn | 2465-8014 | - |
dc.identifier.issn | 2465-8022 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/2881 | - |
dc.description.abstract | Objectives: To assess bioequivalence between two endogenous drugs in 2×2 crossover trial with baseline measurements. Methods: Two statistical methods are applied to assess bioequivalence between two endogenous drugs in 2×2 crossover trials. The first method is based on the current regula tory guideline published by Ministry of Food and Drug Safety (MFDS), which is based on the difference between baseline measurements and responses. The second method is more general approach, so-called general linear model method, which is defined the baseline measurements as covariates. Results: The first method based on current guideline shows that two drugs are not bioequivalent; however, the second method by general linear model shows that two drugs are bioequivalent. When the baselines of the subjects are expected to be highly variable, general linear model approach is more suitable to assess the bioequivalence by adjusting high subjects’ variations. Conclusions: General linear model with covariates should be considered in assessing bioequivalence of endogenous substances when highly subject variations of baseline measurements are expected. | - |
dc.description.abstract | Objectives: To assess bioequivalence between two endogenous drugs in 2×2 crossover trial with baseline measurements. Methods: Two statistical methods are applied to assess bioequivalence between two endogenous drugs in 2×2 crossover trials. The first method is based on the current regula tory guideline published by Ministry of Food and Drug Safety (MFDS), which is based on the difference between baseline measurements and responses. The second method is more general approach, so-called general linear model method, which is defined the baseline measurements as covariates. Results: The first method based on current guideline shows that two drugs are not bioequivalent; however, the second method by general linear model shows that two drugs are bioequivalent. When the baselines of the subjects are expected to be highly variable, general linear model approach is more suitable to assess the bioequivalence by adjusting high subjects’ variations. Conclusions: General linear model with covariates should be considered in assessing bioequivalence of endogenous substances when highly subject variations of baseline measurements are expected. | - |
dc.format.extent | 6 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 한국보건정보통계학회 | - |
dc.title | 기저치를 가진 생물학적 동등성 평가의 통계적 고찰: 내인성 제제사례연구 | - |
dc.title.alternative | Statistical Considerations in Assessing Bioequivalence with Baselines: A Case Study of Endogenous Drugs | - |
dc.type | Article | - |
dc.identifier.doi | 10.21032/jhis.2018.43.2.134 | - |
dc.identifier.bibliographicCitation | 보건정보통계학회지, v.43, no.2, pp 134 - 139 | - |
dc.identifier.kciid | ART002352054 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 139 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 134 | - |
dc.citation.title | 보건정보통계학회지 | - |
dc.citation.volume | 43 | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | 2×2 crossover design | - |
dc.subject.keywordAuthor | Analysis of covariance | - |
dc.subject.keywordAuthor | Baseline measurements | - |
dc.subject.keywordAuthor | Bioequivalence | - |
dc.subject.keywordAuthor | Endogenous drug | - |
dc.subject.keywordAuthor | . | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.